The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

22 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.EBI
Whittier College
A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2.EBI
Xavier University Of Louisiana
Design and Synthesis of Newa-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.EBI
Shanghai Jiao Tong University
Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.EBI
National Taiwan University
Discovery of triazines as potent, selective and orally active PDE4 inhibitors.EBI
Biocrea
Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1.EBI
Xavier University Of Louisiana
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.EBI
F. Hoffmann-La Roche
Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1.EBI
Poznan University Of Medical Sciences
Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.EBI
Universidade Federal De Minas Gerais
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.EBI
University Of Maryland
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.EBI
National Research Institute Of Chinese Medicine
Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.EBI
Astrazeneca
Discovery of a novel class of aldol-derived 1,2,3-triazoles: potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).EBI
Mcmaster University
Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.EBI
University Of Crete
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.EBI
Merck Research Laboratories
Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays.EBI
Instituto PolitéCnico Nacional
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.EBI
University Of Shizuoka
Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.EBI
Astrazeneca
Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.EBI
Seoul National University